Multivariate Cox proportional hazards model for Ki-67 index and treatment interaction for ER positive tumours*
Variable | RFS | BCS | |||||
---|---|---|---|---|---|---|---|
RR | 95% CI | p Value | RR | 95% CI | p Value | ||
*Adjusted for age (continuous), tumour size (T1 v T2), and nodal status (N0 v N+). | |||||||
BCS, breast cancer survival; CI, confidence interval; IDC, invasive ductal carcinomas; ILC, invasive lobular carcinoma; MI, mitotic index; NHG, Nottingham histological grade; RFS, recurrence free survival; RR, relative risk. | |||||||
Ki-67 | Intermediate v low + high | 0.85 | 0.50 to 1.46 | 0.56 | 0.81 | 0.51 to 1.69 | 0.93 |
Treatment | Tamoxifen v control | 0.46 | 0.29 to 0.74 | 0.001 | 0.61 | 0.36 to 1.02 | 0.06 |
Interaction variable | Tamoxifen × Ki-67 | 2.63 | 1.19 to 5.82 | 0.02 | 2.38 | 1.01 to 5.63 | 0.05 |
MI | 2 v 1+3 | 1.22 | 0.80 to 1.88 | 0.35 | 1.04 | 0.64 to 1.69 | 0.88 |
Treatment | Tamoxifen v control | 0.60 | 0.38 to 0.94 | 0.02 | 0.66 | 0.40 to 1.09 | 0.10 |
Interaction variable | Tamoxifen × MI | 1.18 | 0.59 to 2.36 | 0.64 | 1.59 | 0.74 to 3.39 | 0.23 |
NHG | 3 v 1+2 | 1.86 | 1.17 to 2.95 | 0.008 | 2.43 | 1.46 to 4.06 | 0.001 |
Treatment | Tamoxifen v control | 0.62 | 0.40 to 0.96 | 0.03 | 0.76 | 0.45 to 1.25 | 0.28 |
Interaction variable | Tamoxifen × NHG | 0.94 | 0.46 to 1.92 | 0.87 | 0.96 | 0.44 to 2.05 | 0.91 |
Histological type | ILC v IDC | 0.70 | 0.32 to 1.55 | 0.38 | 0.88 | 0.37 to 2.09 | 0.78 |
Treatment | Tamoxifen v control | 0.59 | 0.40 to 0.85 | 0.005 | 0.75 | 0.50 to 1.13 | 0.17 |
Interaction variable | Tamoxifen × type | 1.39 | 0.44 to 4.39 | 0.58 | 1.17 | 0.33 to 4.09 | 0.81 |